Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

European Union: Panel Says European Drug Agency Should Approve Combination HIV Drug Atripla

October 22, 2007

Gilead Sciences Inc., Bristol-Myers Squibb Co., and Merck & Co. said Thursday the EU's Committee for Medicinal Products for Human Use, part of the European Medicines Agency, has recommended its once-a-day HIV drug Atripla be approved for sale. The panel said Atripla should be approved for adults who have not been treated with other HIV therapies. Atripla combines efavirenz, emtricitabine, and tenofovir. An agency ruling is expected by the end of 2007.

Back to other news for October 2007

Adapted from:
Associated Press
10.18.2007


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement